We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 01, 2022

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous SCC

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. Engl. J. Med 2022 Sep 12;[EPub Ahead of Print], ND Gross, DM Miller, NI Khushalani, V Divi, ES Ruiz, EJ Lipson, F Meier, YB Su, PL Swiecicki, J Atlas, JL Geiger, A Hauschild, JH Choe, BGM Hughes, D Schadendorf, VA Patel, J Homsi, JM Taube, AM Lim, R Ferrarotto, HL Kaufman, F Seebach, I Lowy, SY Yoo, M Mathias, K Fenech, H Han, MG Fury, D Rischin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading